…Provides information on CD20, binding epitopes of anti-CD20 monoclonal antibodies (rituximab, ocrelizumab, ofatumumab, ublituximab) and the effects of anti-CD20 MAbs in multiple sclerosis. Includes slides explaining antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). 12 slides Download slide deck…
…Summary of epidemiology, testing and mortality rate; Canada and world statistics. Download COVID-19 slide deck…
…tical COVID (Haas et al. Lancet 2021; epublished 5 May 2021; www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2900947-8). The estimated prevalence of the UK variant (B.1.1.7) at the time of the study was 94.5% of samples, indicating that efficacy against the variant was comparable to what has been reported against the pandemic strain (D614G variant). The UK variant has been associated with a higher risk of mortality (hazard ratio 1.67) (Grint…
…cher et al. and Schultz et al. N Engl J Med 2021, epublished 9 April 2021, free full text at www.nejm.org/doi/full/10.1056/NEJMoa2104840?query=recirc_curatedRelated_article and www.nejm.org/doi/full/10.1056/NEJMoa2104882). One VITT case occurred in the clinical trial of the Johnson & Johnson vaccine (FDA Briefing Document, February 26, 2021. Full text at www.fda.gov/media/146217/download). The FDA paused distribution of that vaccine on April 12 af…
…stration of the Janssen vaccine (Shimabukuro T et al. ACIP, 14 April 2021; free download at www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-04/03-COVID-Shimabukuro-508.pdf). The estimated rate with the Janssen vaccine was 0.87 per million doses administered. CoV-2 serology was negative or not documented in all cases. The report also noted that there were three reports of CVT following administration of 84.7 million doses of the Moderna va…